rituximab + ifosfamide + carboplatin + etoposide + mesna + filgrastim

Rituximab + ifosfamide + carboplatin + etoposide (VP-16) + mesna + G-CSF is a dose-escalated chemoimmunotherapy regimen, often referred to as R-ICEesc or augmented R-ICE. Developed by Memorial Sloan Kettering Cancer Center, it is primarily used as a second-line salvage therapy for patients with primary refractory or relapsed aggressive B-cell non-Hodgkin lymphomas (NHL), such as diffuse large B-cell lymphoma (DLBCL), prior to autologous stem cell transplantation (ASCT). The regimen combines the anti-CD20 monoclonal antibody rituximab with the ICE chemotherapy backbone (ifosfamide, carboplatin, and etoposide). Mesna is included as a uroprotective agent to mitigate ifosfamide-induced hemorrhagic cystitis, and G-CSF is administered to support bone marrow recovery and facilitate peripheral blood progenitor cell mobilization.

Other names

Dose Augmented R-ICEDose-escalated R-ICERituximab + ICE + Mesna + G-CSF